35 research outputs found
Highly potent antisense oligonucleotides: locked nucleic acid gapmers targeting the SARS-CoV-2 RNA genome
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused the current worldwide pandemic and the associated coronavirus disease 2019 with potentially lethal outcome. Although effective vaccines strongly contributed to reduce disease severity, establishing a toolbox to control current and newly emerging coronaviruses of epidemic concern requires the development of novel therapeutic compounds, to treat severely infected individuals and to prevent virus transmission. Here we present a therapeutic strategy targeting the SARS-CoV-2 RNA genome using antisense oligonucleotides (ASOs). We demonstrate that selected locked nucleic acid gapmers have the potency to reduce the in vitro intracellular viral load by up to 96%. Our promising results strongly support the case for further development of our preselected ASOs as therapeutic or prophylactic antiviral agents.Nephrolog
Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women?
CVD
is the primary cause of death among men and women worldwide. Nevertheless, our
comprehension of how CVD progresses in women and elicits clinical outcomes is
lacking, leading CVD to be under-diagnosed and under-treated in women. A clear
example of this differential presentation of CVD pathophysiologies in females
is the strikingly higher prevalence of heart failure with preserved ejection
fraction (HFpEF). Women with a history of preeclampsia, or those that present
co-morbidities such as obesity, hypertension and diabetes mellitus are at
increased risk to develop HFpEF. Long understood to be a critical CVD risk
factor, our understanding of how gender differentially impacts the
development of CVD has been greatly expanded by extensive genomic and
transcriptomic studies.
These studies uncovered a pivotal role for differential miRNA expression in
response to systemic inflammation, where their coordinated expression forms a
post-transcriptional regulatory network that instigates microcirculation defects.
Importantly, the potential sex-biased expression of given miRNAs may explain
sex-specific cardiovascular pathophysiologies in women, such as HFpEF.
Sex-biased miRNAs are regulated by estrogen (E2) in their transcription and
processing or are expressed from loci on the X-chromosome due to incomplete
X-chromosome inactivation. Interestingly,
while E2-induced miRNAs predominantly appear to serve protective functions,
it could be argued that many X-linked miRNAs have been found to challenge
microvascular and myocardial integrity. Therefore, menopausal E2 deficiency,
resulting in protective miRNA loss, and the augmentation of X-linked miRNA
expression, may well contribute to the molecular mechanisms that underlie the
female-specific cardiovascular aetiology in HFpEF.Nephrolog
Emerging roles for RNA-binding proteins as effectors and regulators of cardiovascular disease
Nephrolog
Inflammation, vascular injury and repair in rheumatoid arthritis
The systemic pro-inflammatory state present in patients with rheumatoid arthritis (RA) accelerates the progression of atherosclerosis through chronic endothelial activation. Uncoupling of endothelial nitric oxide synthase plays a central role in the amplification of oxidative signalling pathways that chronically activate and, ultimately, injure the endothelium. Recent studies indicate that the resultant loss of endothelial integrity in patients with RA may also involve defects in the vascular regenerative potential provided by circulating endothelial progenitor cells (EPC). This is most likely the consequence of endothelial cell dysfunction in the bone marrow stroma, which hampers the mobilisation of these EPC to the circulation. In addition, mediators of systemic inflammation in RA can affect a second pathway of vascular regeneration. Under normal circumstances, myeloid CD14+ cells can adopt a pro-angiogenic phenotype that plays a key role in vascular remodelling and collateral formation. However, the chronic systemic inflammation observed in patients with RA may skew the differentiation of bone marrow and circulating CD14+ cells in such a way that these cells lose their capacity to support collateral formation, increasing the risk of cardiovascular disease. Taken together, in patients with RA, the impaired capacity of circulating cells to support vascular regeneration may comprise a novel pathway in the development of premature atherosclerosis.Nephrolog
Inflammation, vascular injury and repair in rheumatoid arthritis
The systemic pro-inflammatory state present in patients with rheumatoid arthritis (RA) accelerates the progression of atherosclerosis through chronic endothelial activation. Uncoupling of endothelial nitric oxide synthase plays a central role in the amplification of oxidative signalling pathways that chronically activate and, ultimately, injure the endothelium. Recent studies indicate that the resultant loss of endothelial integrity in patients with RA may also involve defects in the vascular regenerative potential provided by circulating endothelial progenitor cells (EPC). This is most likely the consequence of endothelial cell dysfunction in the bone marrow stroma, which hampers the mobilisation of these EPC to the circulation. In addition, mediators of systemic inflammation in RA can affect a second pathway of vascular regeneration. Under normal circumstances, myeloid CD14+ cells can adopt a pro-angiogenic phenotype that plays a key role in vascular remodelling and collateral formation. However, the chronic systemic inflammation observed in patients with RA may skew the differentiation of bone marrow and circulating CD14+ cells in such a way that these cells lose their capacity to support collateral formation, increasing the risk of cardiovascular disease. Taken together, in patients with RA, the impaired capacity of circulating cells to support vascular regeneration may comprise a novel pathway in the development of premature atherosclerosis.Nephrolog
Deficiency of Tlr4 Homologue Rp105 Aggravates Outward Remodelling in a Murine Model of Arteriovenous Fistula Failure
Vascular Surger
Silencing of microRNA-132 reduces renal fibrosis by selectively inhibiting myofibroblast proliferation
Vascular nephrologyNephrolog
Targeting the RNA-Binding Protein QKI in Myeloid Cells Ameliorates Macrophage-Induced Renal Interstitial Fibrosis
In the pathophysiologic setting of acute and chronic kidney injury, the excessive activation and recruitment of blood-borne monocytes prompts their differentiation into inflammatory macrophages, a process that leads to progressive glomerulosclerosis and interstitial fibrosis. Importantly, this differentiation of monocytes into macrophages requires the meticulous coordination of gene expression at both the transcriptional and post-transcriptional level. The transcriptomes of these cells are ultimately determined by RNA-binding proteins such as QUAKING (QKI), that define their pre-mRNA splicing and mRNA transcript patterns. Using two mouse models, namely (1) quaking viable mice (qk(v)) and (2) the conditional deletion in the myeloid cell lineage using the lysozyme 2-Cre (QKI(FL/FL;LysM-Cre) mice), we demonstrate that the abrogation of QKI expression in the myeloid cell lineage reduces macrophage infiltration following kidney injury induced by unilateral urethral obstruction (UUO). The qk(v) and QKI(FL/FL;LysM-Cre) mice both showed significant diminished interstitial collagen deposition and fibrosis in the UUO-damaged kidney, as compared to wild-type littermates. We show that macrophages isolated from QKI(FL/FL;LysM-Cre) mice are associated with defects in pre-mRNA splicing. Our findings demonstrate that reduced expression of the alternative splice regulator QKI in the cells of myeloid lineage attenuates renal interstitial fibrosis, suggesting that inhibition of this splice regulator may be of therapeutic value for certain kidney diseases.Nephrolog